Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

NCT07001865 · tracked via the Priya Life Science China tracker

Sponsor

Ningbo No. 1 Hospital

Phase

Observational

Started

2025-04-01

Last updated

2025-06-03

Condition(s) studied

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolically Healthy ObesityHyperuricemia

Study summary

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Accepted

Inclusion Criteria: 1. Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024; 2. Aged 18 years or older at baseline; 3. Completed an abdominal ultrasound examination during the health check-up. Exclusion Criteria: 1. Underweight status at baseline, defined as BMI \< 18.5 kg/m² ； 2. Missing data on height, weight, or components of the metabolic syndrome ; 3. Baseline diagnosis of MASLD or any other liver diseases 4. Baseline diagnosis of hyperuricemia

Primary outcome measure(s)

Incidence of MASLD and Hyperuricemia — 7 years
through study completion

Trial sites (1)

Facility	City	Region	Status
the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang Province 315000 Recruiting	Ningbo	China

More Ningbo No. 1 Hospital trials in China

Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population Recruiting

Screening and Intervention of MASLD in Children Active, not recruiting

Pre-procedural Risk Score-Based Endoscopist Assignment for Pain Reduction in Unsedated Colonoscopy Starting soon

Healthy Weight Management Project for Overweight and Obesity Children Active, not recruiting

Optimizing Intervention Effects in Children and Adolescents Active, not recruiting

Other trials for the same condition

Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM Starting soon

Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia) Recruiting

Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population Recruiting

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease Active, not recruiting

Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07001865 on ClinicalTrials.gov ↗ ← All trials in China